Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhang, Shufang ^a   Liu, Yanxuan ^b   Liu, Zhenxiang ^a   Zhang, Chong ^a   Cao, Hui ^a   Ye, Yongqing ^c   Wang, Shunlan ^a   Zhang, Ying'ai ^a   Xiao, Sifang ^a   Yang, Peng ^a   Li, Jindong ^a   Bai, Zhiming ^a  

^a HAIKOU PEOPLE S HOSPITAL   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c Department of Shanghai Claison Bio Technology ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CISPLATIN; TRANSCRIPTOME;

ALTERNATIVE RNA SPLICING; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CD44 GENE; CDH1 GENE; CLDN7 GENE; CONTROLLED STUDY; FOCAL ADHESION; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; LPHN2 GENE; MALE; MMP2 GENE; MUSCLE INVASIVE BLADDER CANCER; NUCLEOTIDE SEQUENCE; NUMB GENE; PDGFA GENE; PTPRF GENE; QPCR GENE; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UROTHELIAL CARCINOMA OF THE BLADDER; VEGFA GENE; AGED; BIOLOGY; DRUG RESISTANCE; EXON; GENE ONTOLOGY; GENETICS; MOLECULAR GENETICS; MUSCLE; PATHOLOGY; RECURRENT DISEASE; TUMOR GENE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

AGED; ALTERNATIVE SPLICING; CISPLATIN; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; EXONS; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENES, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MOLECULAR SEQUENCE ANNOTATION; MUSCLES; NEOPLASM INVASIVENESS; RECURRENCE; SEQUENCE ANALYSIS, RNA; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84897984333     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091466     Document Type: Article

References (75)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. (Pubitemid 351521864)
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330. (Pubitemid 38041357)
3. Hayne D, Arya M, Quinn MJ, Babb PJ, Beacock CJ, et al. (2004) Current trends in bladder cancer in England and Wales. J Urol 172: 1051-1055. (Pubitemid 39096461)
4. Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. Molecular Pathology 54: 215-221. (Pubitemid 32730394)
5. Williams SG, Stein JP (2004) Molecular pathways in bladder cancer. Urological Research 32: 373-385. (Pubitemid 40137329)
6. Wolff EM, Liang G, Jones PA (2005) Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2: 502-510. (Pubitemid 41594404)
7. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA (2003) Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170: 1085-1087. (Pubitemid 37108084)
8. Herr HW, Dotan Z, Donat SM, Bajorin DF (2007) Defining optimal therapy for muscle invasive bladder cancer. J Urol 177: 437-443. (Pubitemid 46075130)
9. Reddy EP, Reynolds RK, Santos E, Barbacid M (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149-152. (Pubitemid 12006347)
10. Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. PLoS ONE 5: e13821.
11. El-Rifai We, Kamel D, Larramendy ML, Shoman S, Gad Y, et al. (2000) DNA Copy Number Changes in Schistosoma-Associated and Non-Schistosoma-Associated Bladder Cancer. The American Journal of Pathology 156: 871-878.
12. Norskov MS, Frikke-Schmidt R, Bojesen SE, Nordestgaard BG, Loft S, et al. (2011) Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. Pharmacogenomics J 11: 292-299.
13. Wong KM, Hudson TJ, McPherson JD (2011) Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet 12: 407-430.
14. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
15. Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18: 186-193. (Pubitemid 34273739)
16. Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136: 777-793.
17. Venables JP (2004) Aberrant and alternative splicing in cancer. Cancer Research 64: 7647-7654.
18. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, et al. (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8: 349-357. (Pubitemid 46464532)
19. Metzker ML (2010) Sequencing technologies - the next generation. Nat Rev Genet 11: 31-46.
20. Ozsolak F, Milos PM (2011) RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12: 87-98.
21. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10: 57-63.
22. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotech 28: 511-515.
23. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
24. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24: 2343-2364.
25. Katz Y, Wang ET, Airoldi EM, Burge CB (2010) Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 7: 1009-1015.
26. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, et al. (2011) deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data. PLoS Comput Biol 7: e1001138.
27. Kim D, Salzberg SL (2011) TopHat-Fusion: An algorithm for Discovery of Novel Fusion Transcripts. CSHL Biology of Genomes conference.
28. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621-628. (Pubitemid 351911867)
29. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA (2011) Identification of Common Differentially Expressed Genes in Urinary Bladder Cancer. PLoS ONE 6: e18135.
30. Li X, Chen J, Hu X, Huang Y, Li Z, et al. (2011) Comparative mRNA and microRNA Expression Profiling of Three Genitourinary Cancers Reveals Common Hallmarks and Cancer-Specific Molecular Events. PLoS ONE 6: e22570.
31. Mitra AP, Lin H, Datar RH, Cote RJ (2006) Molecular biology of bladder cancer: Prognostic and clinical implications. Clinical Genitourinary Cancer 5: 67-77.
32. Davies B, Waxman J, Wasan H, Abel P, Williams G, et al. (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369. (Pubitemid 23342150)
33. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, et al. (2001) Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57: 675-679.
34. Vasala K, Pääkkö P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker inbladder cancer. Urology 62: 952-957. (Pubitemid 37421256)
35. Marín-Aguilera M, Mengual L, Ribal MJ, Ars E, Ríos J, et al. (2012) Utility of Urothelial mRNA Markers in Blood for Staging and Monitoring Bladder Cancer. Urology 79: 240.e249-240.e215.
36. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, et al. (2001) Urine detection of survivin and diagnosis of bladder cancer. JAMA 285: 324-328. (Pubitemid 32095036)
37. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341: 452-453. (Pubitemid 29362524)
38. Lipponen PK, Eskelinen MJ (1995) Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. Journal of Cancer Research and Clinical Oncology 121: 303-308.
39. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, et al. (2009) Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41: 991-995.
40. Elsamman E, Fukumori T, Kasai T, Nakatsuji H, Nishitani MA, et al. (2006) Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int 97: 1202-1207. (Pubitemid 43907322)
41. Korkolopoulou P, Christodoulou P, Lazaris A, Thomas-Tsagli E, Kapralos P, et al. (2001) Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. Eur Urol 39: 167-177. (Pubitemid 32171183)
42. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, et al. (2010) Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 101: 488-493.
43. Drayton RM, Catto JWF (2012) Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Review of Anticancer Therapy 12: 271-281.
44. Köberle B, Piee-Staffa A (2012) The Molecular Basis of Cisplatin Resistance in Bladder Cancer Cells.
45. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118-132. (Pubitemid 38198740)
46. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis. Annual Review of Cell Biology 9: 541-573.
47. Yeh HJ, Ruit KG, Wang YX, Parks WC, Snider WD, et al. (1991) PDGF A-chain gene is expressed by mammalian neurons during development and in maturity. Cell 64: 209-216. (Pubitemid 121001152)
48. Emerich DF, Vasconcellos AV, Elliott RB, Skinner SJ, Borlongan CV (2004) The choroid plexus: function, pathology and therapeutic potential of its transplantation. Expert Opin Biol Ther 4: 1191-1201. (Pubitemid 39005727)
49. Crews L, Wyss-Coray T, Masliah E (2004) Insights into the pathogenesis of hydrocephalus from transgenic and experimental animal models. Brain Pathology 14: 312-316. (Pubitemid 39095995)
50. Zaravinos A, Lambrou GI, Volanis D, Delakas D, Spandidos DA (2011) Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer. PLoS ONE 6: e18255.
51. Dong L, Bard AJ, Richards WG, Nitz MD, Theodorescu D, et al. (2009) A gene expression ratio-based diagnostic test for bladder cancer. Advances and Applications in Bioinformatics and Chemistry: 17.
52. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, et al. (2004) Gene Expression in the Urinary Bladder. Cancer Research 64: 4040-4048.
53. Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, et al. (2008) Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis. Molecular & Cellular Proteomics 7: 1214-1224. (Pubitemid 352038268)
54. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-1111.
55. Garber M, Grabherr MG, Guttman M, Trapnell C (2011) Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Meth 8: 469-477.
56. Götte M, Yip GW (2006) Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective. Cancer Research 66: 10233-10237. (Pubitemid 44799736)
57. Miyake H, Hara II, Arakawa S, Kamidono S (1999) Utility of Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNA for Detecting Upper Urinary Tract Transitional-Cell Carcinoma. Mol Urol 3: 365-370. (Pubitemid 30078265)
58. Miyake H, Eto H, Arakawa S, Kamidono S, Hara I (2002) Over Expression of CD44V8-10 in Urinary Exfoliated Cells as an Independent Prognostic Predictor in Patients with Urothelial Cancer. The Journal of Urology 167: 1282-1287. (Pubitemid 34132071)
59. Miyake H, Hara I, Kamidono S, Eto H (2004) Multifocal Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract: Molecular Screening of Clonal Origin by Characterizing CD44 Alternative Splicing Patterns. The Journal of Urology 172: 1127-1129. (Pubitemid 39096485)
60. Rorsman F, Bywater M, Knott TJ, Scott J, Betsholtz C (1988) Structural characterization of the human platelet-derived growth factor A-chain cDNA and gene: alternative exon usage predicts two different precursor proteins. Molecular and Cellular Biology 8: 571-577. (Pubitemid 18044873)
61. Heldin CH, Eriksson U, Ostman A (2002) New members of the platelet-derived growth factor family of mitogens. Archives of biochemistry and biophysics 398: 284-290. (Pubitemid 34848597)
62. Heldin CH, Westermark B (1999) Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor. Physiological Reviews 79: 1283-1316. (Pubitemid 29473317)
63. Betsholtz C, Johnsson A, Heldin CH, Westermark B, Lind P, et al. (1986) cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature 320: 695-699. (Pubitemid 16066787)
64. Collins T, Bonthron DT, Orkin SH (1987) Alternative RNA splicing affects function of encoded platelet-derived growth factor A chain. Nature 328: 621-624. (Pubitemid 17103963)
65. Nazarenko I, Hedrén A, Sjödin H, Orrego A, Andrae J, et al. (2011) Brain Abnormalities and Glioma-Like Lesions in Mice Overexpressing the Long Isoform of PDGF-A in Astrocytic Cells. PLoS ONE 6: e18303.
66. Cook JL, Giardina JF, Zhang Z, Re RN (2002) Intracellular Angiotensin II Increases the Long Isoform of PDGF mRNA in Rat Hepatoma Cells. Journal of Molecular and Cellular Cardiology 34: 1525-1537. (Pubitemid 35373675)
67. Langer W, Sohler F, Leder G, Beckmann G, Seidel H, et al. (2010) Exon Array Analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer. BMC Genomics 11: 676.
68. Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, et al. (2011) Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer. Molecular and Cellular Biology 31: 138-150.
69. Chen HJ, Lin CM, Lin CS, Perez-Olle R, Leung CL, et al. (2006) The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathway. Genes Dev 20: 1933-1945. (Pubitemid 44079330)
70. Saadeddin A, Babaei-Jadidi R, Spencer-Dene B, Nateri AS (2009) The Links between Transcription, b-catenin/JNK Signaling, and Carcinogenesis. Molecular Cancer Research 7: 1189-1196.
71. Wang Y (2009) Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy. Molecular Cancer Therapeutics 8: 2103-2109.
72. Jiang H, Wong WH (2009) Statistical inferences for isoform expression in RNASeq. Bioinformatics 25: 1026-1032.
73. Hubbard TJP, Aken BL, Ayling S, Ballester B, Beal K, et al. (2009) Ensembl 2009. Nucleic Acids Research 37: D690-D697.
74. Cook NL, Vink R, Donkin JJ, van den Heuvel C (2009) Validation of reference genes for normalization of real-time quantitative RT-PCR data in traumatic brain injury. J Neurosci Res 87: 34-41.
75. Barber RD, Harmer DW, Coleman RA, Clark BJ (2005) GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 21: 389-395. (Pubitemid 40898499)